RTI Consulting

Executive Summary

RTI Consulting (RTI Bio) is a boutique life-science consultancy founded in 2008 by Thomas Ransohoff and headquartered in Fort Collins, Colorado. The firm specializes in Chemistry, Manufacturing, and Controls (CMC) management for biologics, therapeutics, and vaccines, offering strategic advisory, bioprocess technology implementation, and investor due diligence. With deep expertise and a personalized approach, RTI Consulting serves a niche market of biopharma clients navigating complex regulatory and manufacturing challenges. The company's reputation is built on its founder's decades of experience, which ensures high-quality service but also introduces key-person risk. As a privately held small firm, RTI Consulting operates in a stable niche, with demand driven by the growing biologics pipeline and increasing regulatory scrutiny. However, its growth potential is constrained by scalability limits and competition from larger CROs and in-house teams. Looking ahead, RTI Consulting is well-positioned to benefit from industry tailwinds such as the rise of novel modalities (e.g., cell and gene therapies) and the increasing outsourcing of CMC functions by biopharma companies. The firm's boutique nature allows it to provide tailored, high-touch advisory that larger competitors may not offer. However, reliance on the founder and potential client concentration pose risks. The company has no disclosed funding, valuation, or major public catalysts, and its limited profile suggests a conservative growth trajectory. Overall, RTI Consulting holds a solid position in a specialized segment, but near-term expansion is likely incremental.

Upcoming Catalysts (preview)

• 2026Increased demand for CMC consulting from new FDA guidance on continuous manufacturing75% success